 |
|
Quinolones and False-Positive Urine Screening for Opiates by Immunoassay Technology
Lindsey R. Baden, MD;
Gary Horowitz, MD;
Helen Jacoby, MD;
George M. Eliopoulos, MD
JAMA. 2001;286:3115-3119.
Context Millions of assays are performed each year to monitor for substance abuse in various settings. When common medications cross-react with frequently used testing assays, false-positive results can lead to invalid conclusions.
Objective To evaluate cross-reactivity of quinolone antimicrobials in common opiate screening assays and to assess the in vivo implications of this phenomenon.
Design, Setting, and Participants The reactivity of 13 quinolones (levofloxacin, ofloxacin, pefloxacin, enoxacin, moxifloxacin, gatifloxacin, trovafloxacin, sparfloxacin, lomefloxacin, ciprofloxacin, clinafloxacin, norfloxacin, and nalidixic acid) was tested in 5 commercial opiate screening assays from September 1998 to March 1999. In 6 healthy volunteers, we confirmed the cross-reactivity of levofloxacin or ofloxacin with these opiate screening assays.
Main Outcome Measure Opiate assay activity (threshold for positive result, 300 ng/mL of morphine).
Results Nine of the quinolones caused assay results above the threshold for a positive result in at least 1 of the assays. Four of the assay systems caused false-positive results for at least 1 quinolone. Eleven of the 13 compounds caused some opiate activity by at least 1 assay system. At least 1 compound caused opiate assay activity in all 5 assay systems. Levofloxacin, ofloxacin, and pefloxacin were most likely to lead to a false-positive opiate result. Positive results were obtained in urine from all 6 volunteers.
Conclusion Greater attention to the cross-reactivity of quinolones with immunoassays for opiates is needed to minimize the potential for invalid test interpretation.
Author Affiliations: Departments of Medicine (Drs Baden, Jacoby, and Eliopoulos) and Pathology (Dr Horowitz), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
RELATED ARTICLE
December 26, 2001
JAMA. 2001;286(24):3179-3180.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Rational Use and Interpretation of Urine Drug Testing in Chronic Opioid Therapy
Reisfield et al.
Annals of Clinical & Laboratory Science 2007;37:301-314.
ABSTRACT
| FULL TEXT
Prophylactic Antimicrobial Agents and the Importance of Fitness
Baden
NEJM 2005;353:1052-1054.
FULL TEXT
False-Positive Urine Opiate Screening Associated with Fluoroquinolone Use
Zacher and Givone
The Annals of Pharmacotherapy 2004;38:1525-1528.
ABSTRACT
| FULL TEXT
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Recommendations for the Use of Laboratory Tests to Support Poisoned Patients Who Present to the Emergency Department
Wu et al.
Clin. Chem. 2003;49:357-379.
ABSTRACT
| FULL TEXT
Point-of-Care Testing For Drugs of Abuse in an Urban Emergency Department
Mastrovitch et al.
Annals of Clinical & Laboratory Science 2002;32:383-386.
ABSTRACT
| FULL TEXT
|
